Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 4/2013

01-08-2013 | Case Report

The first case report of non-nosocomial healthcare-associated infective endocarditis due to methicillin-resistant Staphylococcus aureus USA400 in Rio de Janeiro, Brazil

Authors: P. V. Damasco, F. S. Cavalcante, R. C. Chamon, D. C. Ferreira, S. S. Rioja, M. V. Potsch, M. P. Pastura, V. D. Marques, M. B. Castier, E. A. Marques, K. R. N. Santos

Published in: Infection | Issue 4/2013

Login to get access

Abstract

Staphylococcus aureus is the main causal pathogen of infective endocarditis (IE), which may have distinct origins, namely, community, nosocomial, or non-nosocomial healthcare-associated (NNHCA). We report the first case of NNHCA-IE caused by methicillin-resistant S. aureus strain USA400/SCCmec IV in which the combination therapy of rifampin and vancomycin had a favorable outcome for the patient.
Literature
1.
Wu KS, Lee SS, Tsai HC, Wann SR, Chen JK, Sy CL, Wang YH, Tseng YT, Chen YS. Non-nosocomial healthcare-associated infective endocarditis in Taiwan: an under recognized disease with poor outcome. BMC Infect Dis. 2011;11:221.PubMedCrossRef
2.
Milheiriço C, Oliveira DC, de Lencastre H. Update to the multiplex PCR strategy for assignment of mec element types in Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:3374–7.PubMedCrossRef
3.
Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Vandenesch F, Etienne J. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29:1128–32.PubMedCrossRef
4.
Vivoni AM, Diep BA, de Gouveia Magalhães AC, Santos KR, Riley LW, Sensabaugh GF, Moreira BM. Clonal composition of Staphylococcus aureus isolates at a Brazilian university hospital: identification of international circulating lineages. J Clin Microbiol. 2006;44:1686–91.PubMedCrossRef
5.
Cockfield JD, Pathak S, Edgeworth JD, Lindsay SA. Rapid determination of hospital-acquired meticillin-resistant Staphylococcus aureus lineages. J Med Microbiol. 2007;56:614–9.PubMedCrossRef
6.
Benito N, Miró JM, de Lazzari E, Cabell CH, del Río A, Altclas J, Commerford P, Delahaye F, Dragulescu S, Giamarellou H, Habib G, Kamarulzaman A, Kumar AS, Nacinovich FM, Suter F, Tribouilloy C, Venugopal K, Moreno A, Fowler VG Jr, ICE-PCS (International Collaboration on Endocarditis Prospective Cohort Study) investigators. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med. 2009;150:586–94.PubMedCrossRef
7.
Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS, ICE Investigators. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293:3012–21.PubMedCrossRef
8.
Fortes CQ, Espanha CA, Bustorff FP, Zappa BC, Ferreira AL, Moreira RB, Pereira NG, Fowler VG Jr, Deshmukh H. First reported case of infective endocarditis caused by community-acquired methicillin-resistant Staphylococcus aureus not associated with healthcare contact in Brazil. Braz J Infect Dis. 2008;12:541–3.PubMedCrossRef
9.
McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol. 2003;41:5113–20.PubMedCrossRef
10.
Caboclo RM, Cavalcante FS, Iorio NLP, Schuenck RP, Olendzki AN, Félix MJ, Chamon RC, Dos Santos KRN. Methicillin-resistant Staphylococcus aureus in Rio de Janeiro hospitals: dissemination of the USA400/ST1 and USA800/ST5 SCCmec type IV and USA100/ST5 SCCmec type II lineages in a public institution and polyclonal presence in a private one. Am J Infect Control. 2012. doi: 10.​1016/​j.​ajic.​2012.​08.​008.
11.
Damasco PV, Chamon RC, Barbosa AT, da Cunha S, Aquino JH, Cavalcante FS, Dos Santos KR. Involvement of methicillin-susceptible Staphylococcus aureus related to sequence type 25 and harboring pvl genes in a case of carotid cavernous fistula after community-associated sepsis. J Clin Microbiol. 2012;50:196–8.PubMedCrossRef
12.
Gould FK, Denning DW, Elliott TSJ, Foweraker J, Perry JD, Prendergast BD, Sando JAT, Spry MJ, Watkin RW. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the working party of the British Society for antimicrobial chemotherapy. J Antimicrob Chemother. 2012;67:269–89.PubMedCrossRef
13.
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levibe DP, Murray BE, Ryback MJ, Talan DA, Chambers HF. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;53:319.CrossRef
14.
Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of Rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med. 2008;168:805–19.PubMedCrossRef
Metadata
Title
The first case report of non-nosocomial healthcare-associated infective endocarditis due to methicillin-resistant Staphylococcus aureus USA400 in Rio de Janeiro, Brazil
Authors
P. V. Damasco
F. S. Cavalcante
R. C. Chamon
D. C. Ferreira
S. S. Rioja
M. V. Potsch
M. P. Pastura
V. D. Marques
M. B. Castier
E. A. Marques
K. R. N. Santos
Publication date
01-08-2013
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2013
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-013-0430-2

Other articles of this Issue 4/2013

Infection 4/2013 Go to the issue

Case Report

Clostridial abdominal gas gangrene masquerading as a bowel perforation in an advanced-stage ovarian cancer patient

Clinical and Epidemiological Study

The potential impact of biomarker-guided triage decisions for patients with urinary tract infections

Case Report

Successful ganciclovir treatment of primary cytomegalovirus infection containing the UL97 mutation N510S in an intestinal graft recipient

Clinical and Epidemiological Study

Sexual and reproductive health services for people living with HIV/AIDS in Germany: are we up to the challenge?

Case Report

Severe polymyositis due to Toxoplasma gondii in an adult immunocompetent patient: a case report and review of the literature

Clinical and Epidemiological Study

Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits